This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory



Ipsen and Inspiration Partner to Produce Recombinant Factor Therapies

Ipsen and Inspiration Biopharmaceuticals, Inc. announced that they have entered into a partnership to combine their expertise and technologies to develop new recombinant factor products. The two therapies that are farthest along in development are:


  • OBI-1, Ipsen’s recombinant porcine (pig) factor VIII product for the treatment of patients with acquired hemophilia and hemophilia A who have developed an inhibitor to factor VIII. 
  • IB1001, Inspiration’s recombinant factor IX product for the acute and preventive treatment of bleeding in patients with hemophilia B.


Phase III clinical trials for both of these therapies are expected to begin later this year.


Source: Ipsen press release dated January 21, 2010